Moderna, Inc DossierModerna, Inc. reported total revenue of $142 million and an operating loss of $907 million for the quarter ended June 30, 2025, reflecting a period of commercial transition and continued capital investment in its messenger RNA platform. The company's financial results were primarily influenced by the seasonality of its respiratory vaccine sales and significant ongoing expenditures in clinical development. Financial Highlights- Second Quarter 2025 Revenue: $142 million - Quarterly Operating Loss: $907 million - Quarterly Net Loss: $825 million - Diluted Earnings Per Share: -$2.13 - Cash and Cash Equivalents: $1.28 billion - Total Assets: $12.01 billion - Projected Full Year 2025 Revenue: $1.5 billion to $2.2 billion - Projected Full Year 2025 R&D Expenses: $3.6 billion to $3.8 billion Moderna, Inc. is currently executing a strategic realignment to navigate a period of contracted revenues and intense market competition. Management updated the full-year 2025 revenue guidance to a range of $1.5 billion to $2.2... Sign in / Sign up to learn more about Moderna, Inc Continue your research by chatting with our AI financial analyst about Moderna, Inc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings. Start your analysis with these investor-focused questions: - Given Moderna, Inc.'s projected R&D expenses of $3.6 to $3.8 billion for FY2025, which significantly exceeds its revenue guidance of $1.5 to $2.2 billion, and the recent discontinuation of its CMV vaccine program, how should investors evaluate the company's capital allocation strategy and its ability to fund its remaining pipeline to achieve future profitability?
- Moderna, Inc. has experienced mixed outcomes in its patent litigation, with favorable rulings in Europe but an unfavorable decision from the U.S. Patent Trial and Appeal Board in FY2025. How do these ongoing and complex legal battles with competitors like Pfizer/BioNTech impact Moderna, Inc.'s competitive moat and the long-term economic value of its mRNA platform?
- Following the failure of its Phase 3 CMV vaccine trial in October 2025, how has the risk profile of Moderna, Inc.'s growth strategy shifted, and what level of commercial success from its seasonal influenza and flu/COVID combination vaccines is now required to validate its post-pandemic pivot?
- As of Q2 FY2025, Moderna, Inc. reported a significant net cash position and a current ratio of 3.9, yet it is experiencing substantial operating losses and negative free cash flow. How should an analyst reconcile the company's strong balance sheet liquidity with its current operational cash burn when assessing its overall financial health?
- In light of Moderna, Inc.'s high-risk ISS Governance score and its FY2025 proposal for an underwater stock option exchange program, what potential risks do these governance and compensation factors present for long-term investors, and how might they influence the company's ability to execute its strategic initiatives?
|
